Valuation: HCW Biologics Inc.

Market Cap 2.62M 2.34M 2.16M 1.96M 3.66M 248M 3.72M 25.97M 10.28M 130M 9.82M 9.61M 410M P/E 2026 *
-0.04x
P/E 2027 * -0.19x
Enterprise Value 2.62M 2.34M 2.16M 1.96M 3.66M 248M 3.72M 25.97M 10.28M 130M 9.82M 9.61M 410M EV / Sales 2026 *
0.39x
EV / Sales 2027 * -
Free-Float
92.02%
Yield 2026 *
-
Yield 2027 * -
1 day+4.46%
1 week-5.65%
Current month-31.58%
1 month-39.38%
3 months-53.20%
6 months-48.08%
Current year-79.91%
1 week 1.09
Extreme 1.09
1.27
1 month 1.09
Extreme 1.09
1.9
Current year 1.09
Extreme 1.09
23.94
1 year 1.09
Extreme 1.09
23.94
3 years 1.09
Extreme 1.09
604.8
5 years 1.09
Extreme 1.09
1,692
10 years 1.09
Extreme 1.09
1,866
Manager TitleAgeSince
Chief Executive Officer 72 2018-04-01
Director of Finance/CFO 70 2019-09-30
Chief Tech/Sci/R&D Officer 68 2019-04-30
Director TitleAgeSince
Director/Board Member 72 2018-04-01
Chairman 76 2021-05-31
Director/Board Member 61 2021-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
7/29/26 Buy

Chairman

7,736 0.4845%
7/29/26 Buy

Executive/Senior Manager

7,736 0.4845%
7/29/26 Buy

Founder

23,210 1.4535%
Change 5-day change 1-year change 3-year change Capi.($)
+4.46%-5.65%-95.03%-99.74% 2.62M
+2.41%+0.29%+39.41%+73.38% 64.69B
-0.15%+7.50%+11.42%+75.22% 54.78B
+0.57%+4.60%+7.71%+100.57% 53.49B
+0.37%+4.67%+26.68%+54.16% 45.98B
-1.21%+2.32%+21.50%+126.83% 42.94B
-0.37%+5.07%+243.23%+834.48% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
+1.19%-4.98%+26.31%+0.33% 23.97B
-0.38%+5.68%+38.39%+29.86% 23.67B
Average +0.69%+1.61%+33.77%+124.36% 38.31B
Weighted average by Cap. +0.39%+2.73%+46.02%+151.31%

Financials

2026 *2027 *
Net sales 6.68M 5.96M 5.51M 4.99M 9.34M 634M 9.5M 66.3M 26.25M 332M 25.07M 24.53M 1.05B -
Net income -9.62M -8.59M -7.94M -7.19M -13.46M -913M -13.68M -95.52M -37.82M -479M -36.11M -35.34M -1.51B -14.31M -12.78M -11.81M -10.7M -20.02M -1.36B -20.35M -142M -56.25M -712M -53.72M -52.57M -2.24B
Net Debt - -
Projected Income Statement - Annual - HCW Biologics Inc.
Logo HCW Biologics Inc.
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
Employees
35
Date Price Change Volume
26-10-23 US$1.170 +4.46% 80,635
26-10-22 US$1.120 -3.45% 49,323
26-10-21 US$1.160 -0.85% 50,067
26-10-20 US$1.170 -4.88% 98,377
26-10-19 US$1.230 -0.81% 99,113
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.170USD
Average target price
48.00USD
Spread / Average Target
+4,002.56%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - HCW Biologics Inc.
  1. Stock Market
  2. Stocks
  3. HCWB Stock